About bionexus gene lab corp. - BGLC
BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.
BGLC At a Glance
BioNexus Gene Lab Corp.
Tower B, Vertical Business Suite
Kuala Lumpur, Wilayah Perseketuan (Federal Territory) 59200
| Phone | 60-3-7421-6898 | Revenue | 9.77M | |
| Industry | Wholesale Distributors | Net Income | -2,629,043.00 | |
| Sector | Distribution Services | Employees | 18 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
BGLC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.861 |
| Price to Book Ratio | 0.97 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.881 |
| Enterprise Value to Sales | 0.268 |
| Total Debt to Enterprise Value | 0.051 |
BGLC Efficiency
| Revenue/Employee | 542,822.556 |
| Income Per Employee | -146,057.944 |
| Receivables Turnover | 11.398 |
| Total Asset Turnover | 0.97 |
BGLC Liquidity
| Current Ratio | 4.934 |
| Quick Ratio | 4.236 |
| Cash Ratio | 3.636 |
BGLC Profitability
| Gross Margin | 12.755 |
| Operating Margin | -31.519 |
| Pretax Margin | -26.687 |
| Net Margin | -26.907 |
| Return on Assets | -26.108 |
| Return on Equity | -32.213 |
| Return on Total Capital | -26.851 |
| Return on Invested Capital | -31.941 |
BGLC Capital Structure
| Total Debt to Total Equity | 1.381 |
| Total Debt to Total Capital | 1.362 |
| Total Debt to Total Assets | 1.17 |
| Long-Term Debt to Equity | 1.023 |
| Long-Term Debt to Total Capital | 1.009 |